open access

Vol 20, No 6 (2015)
Special Issue Papers
Published online: 2015-11-01
Submitted: 2014-06-23
Get Citation

SBRT for lung oligometastases: Who is the perfect candidate?

Pierina Navarria, Fiorenza De Rose, Anna Maria Ascolese
DOI: 10.1016/j.rpor.2014.11.005
·
Rep Pract Oncol Radiother 2015;20(6):446-453.

open access

Vol 20, No 6 (2015)
Special Issue Papers
Published online: 2015-11-01
Submitted: 2014-06-23

Abstract

Aim

To analyze the literature data about lung oligometastatic patients who underwent SBRT with regard to doses, fractionation, outcomes, response assessment and prognostic factors, trying to define “the right patient” for the local treatment.

Background

“Oligometastatic disease” is defined as a state in which metastases are limited in number and site and characterized by unusual cancer biology and behavior. In this setting local therapy could have a potential curative role. Recently, technological advances in Radiation Oncology permitted the introduction of Stereotactic Body Radiation Therapy (SBRT), a novel treatment modality that delivers ablative dose of radiation to the extra-cranial sites with high precision using single or a small number of fractions.

Materials and methods

We performed a literature search using Medical Subject Heading terms “stereotactic body radiation therapy” and “lung metastases”, considering a period of 10 years.

Results

Many non-randomized studies have shown that SBRT for lung oligometastases is safe and effective, with local control rates of about 80%. To date SBRT represents an alternative and competitive option in patients with lung oligometastatic disease who refuse surgical treatment or unsuitable for surgery. Based on published studies, SBRT might have major benefit for a patient with breast histology, disease-free interval ≥12 months, control of the primary tumor, small lesions, limited number of lesions and higher radiation dose delivered.

Conclusions

Well-designed collaborative trials are necessary to draw final conclusions. To date, the discussion within a multidisciplinary team becomes crucial to perform a careful patients’ selection in the setting of oligometastatic disease.

Abstract

Aim

To analyze the literature data about lung oligometastatic patients who underwent SBRT with regard to doses, fractionation, outcomes, response assessment and prognostic factors, trying to define “the right patient” for the local treatment.

Background

“Oligometastatic disease” is defined as a state in which metastases are limited in number and site and characterized by unusual cancer biology and behavior. In this setting local therapy could have a potential curative role. Recently, technological advances in Radiation Oncology permitted the introduction of Stereotactic Body Radiation Therapy (SBRT), a novel treatment modality that delivers ablative dose of radiation to the extra-cranial sites with high precision using single or a small number of fractions.

Materials and methods

We performed a literature search using Medical Subject Heading terms “stereotactic body radiation therapy” and “lung metastases”, considering a period of 10 years.

Results

Many non-randomized studies have shown that SBRT for lung oligometastases is safe and effective, with local control rates of about 80%. To date SBRT represents an alternative and competitive option in patients with lung oligometastatic disease who refuse surgical treatment or unsuitable for surgery. Based on published studies, SBRT might have major benefit for a patient with breast histology, disease-free interval ≥12 months, control of the primary tumor, small lesions, limited number of lesions and higher radiation dose delivered.

Conclusions

Well-designed collaborative trials are necessary to draw final conclusions. To date, the discussion within a multidisciplinary team becomes crucial to perform a careful patients’ selection in the setting of oligometastatic disease.

Get Citation

Keywords

Lung metastases; SBRT; Oligometastases; SABR

About this article
Title

SBRT for lung oligometastases: Who is the perfect candidate?

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 20, No 6 (2015)

Pages

446-453

Published online

2015-11-01

DOI

10.1016/j.rpor.2014.11.005

Bibliographic record

Rep Pract Oncol Radiother 2015;20(6):446-453.

Keywords

Lung metastases
SBRT
Oligometastases
SABR

Authors

Pierina Navarria
Fiorenza De Rose
Anna Maria Ascolese

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl